- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Kineta Inc.
Headquarters: Seattle, WA, United States of America
Website: http://www.kinetabio.com
Year Founded: 2008
Status: Public
Industry Sector: HealthTechnology
CEO: Shawn P. Iadonato, PhD
Number Of Employees: 5
Enterprise Value: $4,391,815
PE Ratio: -0.21
Exchange/Ticker 1: NASDAQ:KA
Exchange/Ticker 2: N/A
Latest Market Cap: $3,765,500
BioCentury | Jul 28, 2023
Deals
Biotech reverse mergers growing amid improving market conditions
Are 2023’s reverse mergers another sign of an improving biotech environment?
BioCentury | Jul 18, 2023
Management Tracks
Gosebruch named CEO of Neumora
Plus: Petti becomes CEO at Leucid Bio, and updates from Acelyrin, Larimar, Pharming and more
BioCentury | Jun 6, 2022
Deals
Sale of programs to J&J leaves Yumanity as shell for Kineta reverse merger
Combined company to advance Seattle biotech’s cancer programs as Yumanity’s eight-year history in neurodegeneration comes to a close
BioCentury | May 7, 2020
Finance
May 6 Quick Takes: Grail raises year’s largest venture round; plus fresh funds for Insmed, Kura, TG, BerGenBio, Limbix and Kineta
BioCentury | Feb 14, 2020
Targets & Mechanisms
Entrepreneur watch: Iwasaki targets the lymphatic system to clear brain tumors
After starting two companies this year, Yale’s Akiko Iwasaki clears glioblastoma in mice via brain lymphatics
Items per page:
1 - 10 of 30